96 results for "Posch, Martin"
Showing 1–20 · 0.85 seconds · RSS
-
Journal Article Full text
False discovery rate control in two-stage designs
Abstract Background For gene expression or gene association studies with a large number of hypotheses the number of measurements per marker in a conventional single-stage design is often low due to limited resources. Two-stage designs have been proposed where in a first stage promising hypotheses…
Also available at: PubMed Central
-
Journal Article Full text
Post-hoc power estimation in large-scale multiple testing problems
BACKGROUND: The statistical power or multiple Type II error rate in large scale multiple testing problems as, for example, in gene expression microarray experiments, depends on typically unknown parameters and is therefore difficult to assess a priori. However, it has been suggested to estimate the…
-
Journal Article Full text
Adaptive Budgets in Clinical Trials
We consider situations where a drug developer gets access to additional financial resources when a promising result has been observed in a pre-planned interim analysis during a clinical trial which should lead to the registration of the drug. First the option that the drug developer completely puts…
-
Journal Article Full text
Adaptive graph-based multiple testing procedures
Multiple testing procedures defined by directed, weighted graphs have recently been proposed as an intuitive visual tool for constructing multiple testing strategies that reflect the often complex contextual relations between hypotheses in clinical trials. Many well-known sequentially rejective…
-
Journal Article Full text
Cross-platform comparison of microarray data using order restricted inference
MOTIVATION: Titration experiments measuring the gene expression from two different tissues, along with total RNA mixtures of the pure samples, are frequently used for quality evaluation of microarray technologies. Such a design implies that the true mRNA expression of each gene, is either constant…
-
Journal Article Full text
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels
Consider a parallel group trial for the comparison of an experimental treatment to a control, where the second‐stage sample size may depend on the blinded primary endpoint data as well as on additional blinded data from a secondary endpoint. For the setting of normally distributed endpoints, we…
-
Journal Article Full text
Connections between Permutation and t-Tests: Relevance to Adaptive Methods
A permutation test assigns a p-value by conditioning on the data and treating the different possible treatment assignments as random. The fact that the conditional type I error rate given the data is controlled at level α ensures validity of the test even if certain adaptations are made. We show…
-
Journal Article Full text
Impact of adaptive filtering on power and false discovery rate in RNA-seq experiments
BACKGROUND: In RNA-sequencing studies a large number of hypothesis tests are performed to compare the differential expression of genes between several conditions. Filtering has been proposed to remove candidate genes with a low expression level which may not be relevant and have little or no chance…
-
Journal Article Full text
Online control of the False Discovery Rate in group-sequential platform trials
When testing multiple hypotheses, a suitable error rate should be controlled even in exploratory trials. Conventional methods to control the False Discovery Rate assume that all p-values are available at the time point of test decision. In platform trials, however, treatment arms enter and leave…
-
Journal Article Full text
Graph Based, Adaptive, Multiarm, Multiple Endpoint, Two‐Stage Designs
The graph‐based approach to multiple testing is an intuitive method that enables a study team to represent clearly, through a directed graph, its priorities for hierarchical testing of multiple hypotheses, and for propagating the available type‐1 error from rejected or dropped hypotheses to…
-
Journal Article Full text
Sample size reassessment for a two-stage design controlling the false discovery rate
Sample size calculations for gene expression microarray and NGS-RNA-Seq experiments are challenging because the overall power depends on unknown quantities as the proportion of true null hypotheses and the distribution of the effect sizes under the alternative. We propose a two-stage design with an…
-
Journal Article Full text
Adaptive designs for subpopulation analysis optimizing utility functions
If the response to treatment depends on genetic biomarkers, it is important to identify predictive biomarkers that define (sub-)populations where the treatment has a positive benefit risk balance. One approach to determine relevant subpopulations are subgroup analyses where the treatment effect is…
-
Journal Article Full text
Evaluation of the Fill-it-up-design to use historical control data in randomized clinical trials with two arm parallel group design
PURPOSE: In the context of clinical research, there is an increasing need for new study designs that help to incorporate already available data. With the help of historical controls, the existing information can be utilized to support the new study design, but of course, inclusion also carries the…
-
Journal Article Full text
Bridging the gap: a review of dose-investigation studies in paediatric investigation plans
-
Journal Article Full text
Estimation after blinded sample size reassessment
Blinded sample size reassessment is a popular means to control the power in clinical trials if no reliable information on nuisance parameters is available in the planning phase. We investigate how sample size reassessment based on blinded interim data affects the properties of point estimates and…
-
Journal Article Full text
Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials
Mid-study design modifications are becoming increasingly accepted in confirmatory clinical trials, so long as appropriate methods are applied such that error rates are controlled. It is therefore unfortunate that the important case of time-to-event endpoints is not easily handled by the standard…
-
Journal Article Full text
Fallback tests for co‐primary endpoints
When efficacy of a treatment is measured by co‐primary endpoints, efficacy is claimed only if for each endpoint an individual statistical test is significant at level α. While such a strategy controls the family‐wise type I error rate (FWER), it is often strictly conservative and allows for no…
-
Journal Article Full text
A multiple comparison procedure for dose‐finding trials with subpopulations
Identifying subgroups of patients with an enhanced response to a new treatment has become an area of increased interest in the last few years. When there is knowledge about possible subpopulations with an enhanced treatment effect before the start of a trial it might be beneficial to set up a…